Breaking News Instant updates and real-time market news.

IONS

Ionis Pharmaceuticals

$44.26

1.35 (3.15%)

16:46
04/21/17
04/21
16:46
04/21/17
16:46

Ionis Pharmaceuticals files to sell common stock, no amount given

  • 22

    Apr

  • 24

    May

IONS Ionis Pharmaceuticals
$44.26

1.35 (3.15%)

03/10/17
GSCO
03/10/17
DOWNGRADE
Target $25
GSCO
Sell
Ionis Pharmaceuticals downgraded to Sell from Neutral at Goldman
Goldman analyst Salveen Richter downgraded Ionis Pharmaceuticals to Sell and lowered its price target to $25 from $28. The analyst commented Ionis has a "lackluster" track record of developing successful drugs and ongoing toxicity across multiple drugs. If volanesorsen is approved for FCS, Richter expects safety/compliance issues and the launch focus on specialists will result in limited returns, similar to drug Kynamro for high cholesterol.
03/10/17
03/10/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Dollar General (DG) downgraded to Neutral from Buy at Buckingham with the firm's analyst saying the environment has become more difficult since the bullish analyst day last spring. The firm's analyst said shares do not appear to fully factor in sales and margin challenges and sees risk to Street expectations. 2. MEDNAX (MD) downgraded to Neutral from Overweight at JPMorgan with analyst Gary Taylor citing valuation following the recent rally in the shares. The analyst says he can't with confidence bump up his $69 price target given the multi-year slowdown of organic growth and its high Medicaid payor exposure. 3. Loxo Oncology (LOXO) downgraded to Neutral from Buy at Citi with analyst Yigal Nochomovitz saying the stock is now fairly valued. The reflect the equity financing in January which expanded the share count and rising R&D spend, the analyst cut his price target for the shares to $45 from $49. He believes, however, that Loxo management is executing the business plan well. 4. Kimberly-Clark (KMB) downgraded to Hold on competition, valuation at Societe Generale with analyst Iain Simpson saying price competition in the U.S. has picked up as P&G is becoming more aggressive with its mid-tier Luvs and competition in Brazil and China remains "tough." The analyst expects cost cutting to drive margins and views cash returns as "robust," but said valuation has caught up with fundamentals. 5. Ionis Pharmaceuticals (IONS) downgraded to Sell from Neutral at Goldman with analyst Salveen Richter saying Ionis has a "lackluster" track record of developing successful drugs and ongoing toxicity across multiple drugs. If volanesorsen is approved for FCS, Richter expects safety/compliance issues and the launch focus on specialists will result in limited returns, similar to drug Kynamro for high cholesterol. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/13/17
WELS
03/13/17
NO CHANGE
WELS
Ionis Pharma should be bought after negative note, says Wells Fargo
Wells Fargo recommends that investors buy Ionis "ahead of multiple upcoming value drivers" Although another firm on Friday called Ionis' antisense platform a "mirage," that has not realized value, four products that use the platform have been approved, and analysts expect the company to generate $440M in revenue this year, Wells stated. The firm thinks that the company's results can beat expectations.
03/17/17
GSCO
03/17/17
NO CHANGE
Target $108
GSCO
Buy
AveXis price target raised to $108 on higher confidence in AVXS-101 at Goldman
After AveXis (AVXS) reported results for its Phase 1 study of AVXS-101 in spinal muscular atrophy, Goldman Sachs analyst Salveen Richter said data for the treatment continues to impress and increased his probability of success for the drug to 85% from 65% previously. The analyst, who views AVXS-101 as a key competitive threat to Biogen (BIIB) and Ionis' (IONS) Spinraza as the potential first-line treatment for SMA, raised his price target on AveXis to $108 from $91 and keeps a Buy rating on the shares.

TODAY'S FREE FLY STORIES

MDXG

MiMedx

$12.34

-0.82 (-6.23%)

16:05
09/20/17
09/20
16:05
09/20/17
16:05
Hot Stocks
MiMedx responds to two "deceptive short seller articles" »

MiMedx Group responded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

LUNA

Luna Innovations

$1.64

0.05 (3.14%)

16:05
09/20/17
09/20
16:05
09/20/17
16:05
Hot Stocks
Luna Innovations announces stock repurchase program »

Luna Innovations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AERI

Aerie Pharmaceuticals

$53.40

-5.2 (-8.87%)

16:03
09/20/17
09/20
16:03
09/20/17
16:03
Hot Stocks
Aerie announces FDA Advisory Committee meeting for Rhopressa 0.02% »

Aerie Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 28

    Feb

AMD

AMD

$13.12

0.04 (0.31%)

, TSLA

Tesla

$375.10

-9.9 (-2.57%)

15:57
09/20/17
09/20
15:57
09/20/17
15:57
Periodicals
Tesla working with AMD on self-driving car AI chip, CNBC says »

Tesla (TSLA) is using AMD…

AMD

AMD

$13.12

0.04 (0.31%)

TSLA

Tesla

$375.10

-9.9 (-2.57%)

NVDA

Nvidia

$187.35

-0.2 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

AMD

AMD

$13.12

0.04 (0.31%)

, TSLA

Tesla

$375.10

-9.9 (-2.57%)

15:54
09/20/17
09/20
15:54
09/20/17
15:54
Periodicals
Breaking Periodicals news story on AMD, Tesla »

Tesla working with AMD on…

AMD

AMD

$13.12

0.04 (0.31%)

TSLA

Tesla

$375.10

-9.9 (-2.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

15:50
09/20/17
09/20
15:50
09/20/17
15:50
General news
More from Yellen: »

More from Yellen: FOMC…

VIX

Volatility Index S&P 500 Options

15:40
09/20/17
09/20
15:40
09/20/17
15:40
Options
Active trading in VIX calls as players replace expiring positions »

Active trading in VIX…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:35
09/20/17
09/20
15:35
09/20/17
15:35
General news
Yellen on the FRB »

Yellen on the FRB: she is…

DMPI

DelMar Pharmaceuticals

$1.12

0.0294 (2.70%)

15:33
09/20/17
09/20
15:33
09/20/17
15:33
Syndicate
DelMar Pharmaceuticals announces $10M registered direct offering at-the-market »

DelMar Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$47.94

0.27 (0.57%)

15:30
09/20/17
09/20
15:30
09/20/17
15:30
Options
Far downside put buying in Morgan Stanley »

Far downside put buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 02

    Oct

  • 22

    Oct

JWN

Nordstrom

$46.13

-0.09 (-0.19%)

15:25
09/20/17
09/20
15:25
09/20/17
15:25
Conference/Events
Nordstrom management to meet with Wolfe Research »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BG

Bunge

$71.38

-1.1 (-1.52%)

15:25
09/20/17
09/20
15:25
09/20/17
15:25
Options
Bunge call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:25
09/20/17
09/20
15:25
09/20/17
15:25
General news
More from Yellen on inflation »

More from Yellen on…

WFC

Wells Fargo

$53.95

0.591 (1.11%)

15:22
09/20/17
09/20
15:22
09/20/17
15:22
Hot Stocks
Chair Yellen calls Wells Fargo actions 'unacceptable' »

Fed Chair Janet Yellen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 12

    Oct

  • 22

    Oct

  • 29

    Nov

  • 15

    Jan

15:20
09/20/17
09/20
15:20
09/20/17
15:20
General news
The FOMC dot-plot projections »

The FOMC dot-plot…

$NSD

NASDAQ Market Internals

15:17
09/20/17
09/20
15:17
09/20/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$75.04

-0.96 (-1.26%)

15:16
09/20/17
09/20
15:16
09/20/17
15:16
Recommendations
Alnylam analyst commentary  »

Alnylam price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

$NYE

NYSE Market Internals

15:16
09/20/17
09/20
15:16
09/20/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LII

Lennox

$170.00

4.17 (2.51%)

15:14
09/20/17
09/20
15:14
09/20/17
15:14
Conference/Events
Lennox management to meet with Wolfe Research »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

VXX

iPath S&P 500 VIX Short-Term Futures

$41.28

0.37 (0.90%)

15:10
09/20/17
09/20
15:10
09/20/17
15:10
Options
Notable put write in longer-term options on the Short-term VIX ETN »

Notable put write in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:09
09/20/17
09/20
15:09
09/20/17
15:09
General news
Yellen repeats intention to serve out term as chair »

Fed Chair Yellen added…

DLPH

Delphi

$100.88

-0.02 (-0.02%)

, BBRY

BlackBerry

$9.14

-0.12 (-1.30%)

15:05
09/20/17
09/20
15:05
09/20/17
15:05
Hot Stocks
Delphi confirms autonomous driving partnership agreement with BlackBerry »

Delphi Automotive (DLPH)…

DLPH

Delphi

$100.88

-0.02 (-0.02%)

BBRY

BlackBerry

$9.14

-0.12 (-1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

UAA

Under Armour

$16.43

-0.38 (-2.26%)

15:00
09/20/17
09/20
15:00
09/20/17
15:00
Options
Under Armour attracts a bullish option play as the slide in shares continues »

Under Armour attracts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

14:55
09/20/17
09/20
14:55
09/20/17
14:55
General news
Fed Chair Yellen reiterated the FOMC statement »

Fed Chair Yellen…

MLHR

Herman Miller

$34.95

0.1 (0.29%)

14:49
09/20/17
09/20
14:49
09/20/17
14:49
Options
Herman Miller options imply 9.6% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.